Abstract #1907
A NIR830-Bevacizumab-Conjugated Iron Oxide Nanoparticle Probe for Vascular Endothelial Growth Factor (VGEF) Targeted MRI
Run Lin 1,2 , Jing Huang 1 , Liya Wang 1 , Yuancheng Li 1 , Prieto Ventura Veronica E 1 , Kevin Kim 1 , and Hui Mao 1
1
Department of Radiology and Imaging
Sciences, Emory University School of Medicine, Atlanta,
GA, United States,
2
Department
of Radiology, the First Affiliated Hospital of Sun
Yat-Sen University, Guangzhou, Guangdong, China
Vascular endothelial growth factor (VEGF) plays a
pivotal role in the cascade of development and
progression of cancers by promoting angiogenesis.
Targeting this biomarker would be a logical strategy for
imaging based cancer detection and anti-angiogenesis
treatment. Bevacizumab is a recombinant humanized
monoclonal antibody directly against VEGF and is
currently used in clinic for treating various cancers
with VEGF overexpression. In this study, a VEGF targeted
molecular imaging probe was developed by conjugating
near infrared dye (NIR830) labeled bevacizumab to
magnetic iron oxide nanoparticles (IONP) for optical and
magnetic resonance (MR) imaging of cancers
overexpressing VEGF.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
